Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations

Steroids

Volumn 90, Issue , 2014, Pages 44-52

  Fan, Ping ^a   Craig Jordan, V ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Estrogen; Estrogen induced apoptosis; Resistance; Selective estrogen receptor modulator (SERM)

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

APOPTOSIS; BREAST TUMOR; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGENS; HUMANS; RALOXIFENE HYDROCHLORIDE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84908703414     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.06.002     Document Type: Article

References (102)

1. V.C. Jordan, and A.M.H. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25
2. M. Dowsett, J. Cuzick, J. Ingle, A. Coates, J. Forbes, and J. Bliss Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
3. E.A. Ariazi, J.S. Lewis-Wambi, S.D. Gill, J.R. Pyle, J.L. Ariazi, and H.R. Kim Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant J Steroid Biochem Mol Biol 102 2006 128 138
4. C.K. Osborne, J. Pippen, S.E. Jones, L.M. Parker, M. Ellis, and S. Come Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
5. A. Howell, J.F. Robertson, J. Quaresma Albano, A. Aschermannova, L. Mauriac, and U.R. Kleeberg Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
6. E.V. Jensen, and V.C. Jordan The estrogen receptor: a model for molecular medicine Clin Cancer Res 9 2003 1980 1989
7. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, and W.M. Cronin Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
8. V.C. Jordan Tamoxifen: catalyst for the change to targeted therapy Eur J Cancer 44 2008 30 38
9. R.D. Gelber, B.F. Cole, A. Goldhirsch, C. Rose, B. Fisher, and C.K. Osborne Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival Lancet 347 1996 1066 1071
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: p. 1687-717.
11. C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, and S. Darby Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
12. V.C. Jordan Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications Breast Cancer Res Treat 3 1983 S73 S86
13. The aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 [supplement].
14. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, and V. Raina Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
15. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, and S. Ashley Overview of the main outcomes in breast cancer prevention trials Lancet 361 2003 296 300
16. V.C. Jordan The rise of raloxifene and the fall of invasive breast cancer J Natl Cancer Inst 100 2008 831 833
17. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, and J.A. Cauley The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 1999 2189 2197
18. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
19. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins The study of tamoxifen and raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial JAMA 295 2006 2727 2741
20. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Update of the National Surgical Adjuvant Breast and Bowel Project Study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer Cancer Prev Res 3 2010 696 706
21. Jordan VC. A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause 2014; [Epub ahead of print].
22. J.C. Gallagher, H. Shi, S. Mirkin, and A.A. Chines Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens Menopause 20 2013 1126 1132
23. V.C. Jordan Tamoxifen (ICI 46,474) as a targeted therapy to treat and prevent breast cancer Br J Pharmacol 147 2006 S269 S276
24. L.J. Lerner, and V.C. Jordan Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture Cancer Res 50 1990 4177 4189
25. V.C. Jordan SERMs: meeting the promise of multifunctional medicines J Natl Cancer Inst 99 2007 350 356
26. R.M. O'Regan, A. Cisneros, G.M. England, J.I. MacGregor, H.D. Muenzner, and V.J. Assikis Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth J Natl Cancer Inst 90 1998 1552 1558
27. T.A. Grese, J.P. Sluka, H.U. Bryant, G.J. Cullen, A.L. Glasebrook, and C.D. Jones Molecular determinants of tissue selectivity in estrogen receptor modulators Proc Natl Acad Sci USA 94 1997 14105 14110
28. T. Fornander, L.E. Rutqvist, B. Cedermark, U. Glas, A. Mattsson, and C. Silfverswärd Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 1989 117 120
29. M.M. Gottardis, S.P. Robinson, P.G. Satyaswaroop, and V.C. Jordan Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res 48 1988 812 815
30. M.M. Gottardis, M.E. Ricchio, P.G. Satyaswaroop, and V.C. Jordan Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimu lated human endometrial carcinoma (EnCa101) in athymic mice Cancer Res 50 1990 3189 3192
31. J.V. Pinkerton, J.A. Harvey, R. Lindsay, K. Pan, A.A. Chines, and S. Mirkin Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial J Clin Endocrinol Metab 99 2014 E189 E198
32. S. Mirkin, B.S. Komm, K. Pan, and A.A. Chines Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric 16 2013 338 346
33. Y. Shang, and M. Brown Molecular determinants for the tissue specificity of SERMs Science 295 2002 2465 2468
34. S.A. Onate, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley Sequence and characterization of a coactivator for the steroid hormone receptor superfamily Science 270 1995 1354 1357
35. C.L. Smith, and B.W. O'Malley Coregulator function: a key to understanding tissue specificity of selective receptor modulators Endocr Rev 25 2004 45 71
36. Y. Shang, X. Hu, J. DiRenzo, M.A. Lazar, and M. Brown Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription Cell 103 2000 843 852
37. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, and D.A. Agard The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
38. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, and O. Engström Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 1997 753 758
39. A.L. Wijayaratne, S.C. Nagel, L.A. Paige, D.J. Christensen, J.D. Norris, and D.M. Fowlkes Comparative analyses of mechanistic differences among antiestrogens Endocrinology 140 1999 5828 5840
40. F. Schaufele, C.Y. Chang, W. Liu, J.D. Baxter, S.K. Nordeen, and Y. Wan Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor Mol Endocrinol 14 2000 2024 2039
41. J.M. Hall, D.P. McDonnell, and K.S. Korach Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements Mol Endocrinol 16 2002 469 486
42. J. Xu, R.C. Wu, and B.W. O'Malley Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family Nat Rev Cancer 9 2009 615 630
43. S. Sengupta, I. Obiorah, P.Y. Maximov, R. Curpan, and V.C. Jordan Molecular mechanism of action of bisphenol and bisphenol a mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells Br J Pharmacol 169 2013 167 178
44. J.S. Lewis-Wambi, H. Kim, R. Curpan, R. Grigg, M.A. Sarker, and V.C. Jordan The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1 Mol Pharmacol 80 2011 610 620
45. S.E. Wardell, E.R. Nelson, C.A. Chao, and D.P. McDonnell Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease Clin Cancer Res 19 2013 2420 2431
46. V.C. Jordan, and B.W. O'Malley Selective estrogen-receptor modulators and antihormonal resistance in breast cancer J Clin Oncol 25 2007 5815 5824
47. H. Brauch, and M. Schwab Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer Br J Clin Pharmacol 77 2014 695 703
48. D.M. Wolf, and V.C. Jordan The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain Breast Cancer Res Treat 31 1994 129 138
49. D.M. Wolf, and V.C. Jordan Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice Breast Cancer Res Treat 31 1994 117 127
50. H. Liu, W.C. Park, D.J. Bentrem, K.P. McKian, L. Reyes Ade, and J.A. Loweth Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells J Biol Chem 277 2002 9189 9198
51. H. Liu, E.S. Lee, A. Deb Los Reyes, J.W. Zapf, and V.C. Jordan Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex Cancer Res 61 2001 3632 3639
52. J.M. Schafer, H. Liu, D.A. Tonetti, and V.C. Jordan The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor Cancer Res 59 1999 4308 4313
53. A.S. Levenson, W.H. Catherino, and V.C. Jordan Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor J Steroid Biochem Mol Biol 60 1997 261 268
54. A.S. Levenson, and V.C. Jordan The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor Cancer Res 58 1998 1872 1875
55. R. Jeselsohn, R. Yelensky, G. Buchwalter, G. Frampton, F. Meric-Bernstam, and A.M. Gonzalez-Angulo Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer Clin Cancer Res 20 2014 1757 1767
56. K. Merenbakh-Lamin, N. Ben-Baruch, A. Yeheskel, A. Dvir, L. Soussan-Gutman, and R. Jeselsohn D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer Cancer Res 73 2013 6856 6864
57. S. Li, D. Shen, J. Shao, R. Crowder, W. Liu, and A. Prat Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts Cell Rep 4 2013 1116 1130
58. D.R. Robinson, Y.M. Wu, P. Vats, F. Su, R.J. Lonigro, and X. Cao Activating ESR1 mutations in hormone-resistant metastatic breast cancer Nat Genet 45 2013 1446 1451
59. W. Toy, Y. Shen, H. Won, B. Green, R.A. Sakr, and M. Will ESR1 ligand-binding domain mutations in hormone-resistant breast cancer Nat Genet 45 2013 1439 1445
60. M.M. Gottardis, and V.C. Jordan Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res 48 1988 5183 5187
61. M.M. Gottardis, R.J. Wagner, E.C. Borden, and V.C. Jordan Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro Cancer Res 49 1989 4765 4769
62. K. Yao, E.S. Lee, D.J. Bentrem, G. England, J.I. Schafer, and R.M. O'Regan Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 2028 2036
63. M.M. Gottardis, S.Y. Jiang, M.H. Jeng, and V.C. Jordan Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens Cancer Res 49 1989 4090 4093
64. E.S. Lee, J.M. Schafer, K. Yao, G. England, R.M. O'Regan, and A. De Los Reyes Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 4893 4899
65. V.C. Jordan Selective estrogen receptor modulation: concept and consequences in cancer Cancer Cell 5 2004 207 213
66. D.M. Wolf, and V.C. Jordan A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy Recent Results Cancer Res 127 1993 23 33
67. V.C. Jordan The 38th David A. Karnofsky Lecture. The paradoxical actions of estrogen in breast cancer: survival or death? J Clin Oncol 26 2008 3073 3082
68. V.C. Jordan, J.S. Lewis, C. Osipo, and D. Cheng The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy Breast 14 2005 624 630
69. P.E. Lønning, P.D. Taylor, G. Anker, J. Iddon, L. Wie, and L.M. Jørgensen High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res Treat 67 2001 111 116
70. M.J. Ellis, F. Gao, F. Dehdashti, D.B. Jeffe, P.K. Marcom, and L.A. Carey Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 2009 774 780
71. A. Howell, D.J. Dodwell, H. Anderson, and J. Redford Response after withdrawal of tamoxifen and progestogens in advanced breast cancer Ann Oncol 3 1992 611 617
72. Y. Berthois, J.A. Katzenellenbogen, and B.S. Katzenellenbogen Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture Proc Natl Acad Sci USA 83 1986 2496 2500
73. W.V. Welshons, and V.C. Jordan Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture Eur J Cancer Clin Oncol 23 1987 1935 1939
74. B.S. Katzenellenbogen, K.L. Kendra, M.J. Norman, and Y. Berthois Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens Cancer Res 47 1987 4355 4360
75. S. Masamura, S.J. Santner, D.F. Heitjan, and R.J. Santen Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells J Clin Endocrinol Metab 80 1995 2918 2925
76. W. Yue, J.P. Wang, M. Conaway, S. Masamura, Y. Li, and R.J. Santen Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol Endocrinology 143 2002 3221 3229
77. R.X. Song, G. Mor, F. Naftolin, R.A. McPherson, J. Song, and Z. Zhang Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol J Natl Cancer Inst 93 2001 714 723
78. A. Haddow, J.M. Watkinson, E. Paterson, and P.C. Koller Influence of synthetic oestrogens upon advanced malignant disease BMJ 23 1944 393 398
79. V.C. Jordan, H. Liu, and R. Dardes Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death J Natl Cancer Inst 94 2002 1173
80. S.Y. Jiang, D.M. Wolf, J.M. Yingling, C. Chang, and V.C. Jordan An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol Mol Cell Endocrinol 90 1992 77 86
81. J.J. Pink, S.Y. Jiang, M. Fritsch, and V.C. Jordan An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein Cancer Res 55 1995 2583 2590
82. J.S. Lewis-Wambi, H.R. Kim, C. Wambi, R. Patel, J.R. Pyle, and A.J. Klein-Szanto Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis Breast Cancer Res 10 2008 R104
83. J.S. Lewis-Wambi, R. Swaby, H. Kim, and V.C. Jordan Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer J Steroid Biochem Mol Biol 114 2009 33 39
84. E.E. Sweeney, P. Fan, and V.C. Jordan Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells Int J Oncol 44 2014 1529 1538
85. J.S. Lewis, C. Osipo, K. Meeke, and V.C. Jordan Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal J Steroid Biochem Mol Biol 94 2005 131 141
86. J.S. Lewis, K. Meeke, C. Osipo, E.A. Ross, N. Kidawi, and T. Li Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation J Natl Cancer Inst 97 2005 1746 1759
87. E.A. Ariazi, H.E. Cunliffe, J.S. Lewis-Wambi, M.J. Slifker, A.L. Willis, and P. Ramos Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time Proc Natl Acad Sci USA 108 2011 18879 18886
88. C. Osipo, C. Gajdos, H. Liu, B. Chen, and V.C. Jordan Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer J Natl Cancer Inst 95 2003 1597 1608
89. H. Liu, E.S. Lee, C. Gajdos, S.T. Pearce, B. Chen, and C. Osipo Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo J Natl Cancer Inst 95 2003 1586 1597
90. C. Osipo, K. Meeke, D. Cheng, A. Weichel, A. Bertucci, and H. Liu Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer Int J Oncol 30 2007 509 520
91. I.E. Obiorah, S. Sengupta, R. Curpan, and V.C. Jordan Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer Mol Pharmacol 85 2014 789 799
92. Obiorah I, S. Sengupta, P. Fan, and V.C. Jordan Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death Br J Cancer 110 2014 1488 1496
93. I. Obiorah, and V.C. Jordan Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality Menopause 20 2013 372 382
94. P. Fan, O.L. Griffith, F.A. Agboke, P. Anur, X. Zou, and R.E. McDaniel C-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells Cancer Res 73 2013 4510 4520
95. P. Fan, R.E. McDaniel, H.R. Kim, D. Clagett, B. Haddad, and V.C. Jordan Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines Eur J Cancer 48 2012 3488 3498
96. P. Fan, F.A. Agboke, R.E. McDaniel, E.E. Sweeney, X. Zou, and K. Creswell Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells Eur J Cancer 50 2014 457 468
97. G.M. Balaburski, R.C. Dardes, M. Johnson, B. Haddad, F. Zhu, and E.A. Ross Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance Int J Oncol 37 2010 387 398
98. I.R. Hutcheson, J.M. Knowlden, T.A. Madden, D. Barrow, J.M. Gee, and A.E. Wakeling Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res Treat 81 2003 81 93
99. S. Massarweh, C.K. Osborne, C.J. Creighton, L. Qin, A. Tsimelzon, and S. Huang Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 2008 826 833
100. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat Rev Drug Discov 2 2003 205 213
101. V.C. Jordan, I. Obiorah, P. Fan, H.R. Kim, E. Ariazi, and H. Cunliffe The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities Breast 20 2011 S1 S11
102. V.C. Jordan A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention Cancer Res 69 2009 1243 1254